Northwestern Mutual Wealth Management Co. Acquires New Holdings in Biogen Inc. $BIIB

Northwestern Mutual Wealth Management Co. bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,299 shares of the biotechnology company’s stock, valued at approximately $1,577,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bell Investment Advisors Inc bought a new position in Biogen in the second quarter valued at about $27,000. Reflection Asset Management acquired a new stake in shares of Biogen during the fourth quarter valued at about $25,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. MV Capital Management Inc. bought a new stake in shares of Biogen during the fourth quarter worth about $34,000. Finally, Strive Financial Group LLC bought a new stake in shares of Biogen during the fourth quarter worth about $35,000. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of BIIB opened at $220.77 on Wednesday. The business has a 50-day moving average of $206.42 and a 200-day moving average of $195.12. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The company has a market capitalization of $32.62 billion, a price-to-earnings ratio of 39.07, a price-to-earnings-growth ratio of 6.80 and a beta of 0.17. Biogen Inc. has a 1 year low of $131.52 and a 1 year high of $222.85.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 12.39 earnings per share for the current year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Analyst Ratings Changes

BIIB has been the subject of a number of research reports. Evercore initiated coverage on shares of Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. HSBC reissued a “reduce” rating and set a $157.00 target price on shares of Biogen in a report on Monday, July 6th. Needham & Company LLC upped their price target on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research report on Monday, June 29th. UBS Group raised their price target on shares of Biogen from $225.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Royal Bank Of Canada lifted their price target on shares of Biogen from $240.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and an average target price of $227.79.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.